All of the following antibiotics are 50S ribosomal inhibitors, EXCEPT?
Ivermectin is a:
Which of the following agents does not cause pseudomembranous enterocolitis?
A patient with HIV disease is on Highly Active Anti Retroviral Therapy (HAART). The patient develops tuberculosis. Which one of the following anti-tubercular drugs interferes with HAART?
All of the following toxicities are known with linezolid, EXCEPT:
Which drug is useful in treating chloroquine-resistant malaria?
Which of the following aminoglycosides carries the highest risk of neuromuscular blockade?
Which is the longest acting oral sulfonamide?
Ivermectin acts by?
Which of the following drugs is useful in the treatment of infection by Mycobacterium avium complex?
Explanation: Protein synthesis inhibitors are a high-yield topic for NEET-PG. These drugs work by binding to either the 30S or 50S subunits of the bacterial ribosome [1]. Why Streptomycin is the correct answer: Streptomycin is an **Aminoglycoside** [3]. Aminoglycosides (along with Tetracyclines) bind to the **30S ribosomal subunit** [2, 1]. They interfere with the initiation complex, cause misreading of mRNA, and break up polysomes into non-functional monosomes [2]. Because it acts on the 30S subunit, it is the exception in this list. Analysis of Incorrect Options (50S Inhibitors): * **Chloramphenicol:** Binds to the 50S subunit and inhibits the enzyme **peptidyl transferase**, preventing peptide bond formation [1]. * **Erythromycin:** A Macrolide that binds to the 50S subunit and inhibits **translocation** (the movement of tRNA from the A-site to the P-site) [1]. * **Linezolid:** An Oxazolidinone that binds to the 23S fraction of the 50S subunit. It is unique because it prevents the **formation of the 70S initiation complex** [1]. Clinical Pearls for NEET-PG: * **Mnemonic for 50S inhibitors:** "**C**EL" (**C**hloramphenicol, **E**rythromycin/Macrolides, **L**inezolid/Clindamycin). * **Mnemonic for 30S inhibitors:** "**A**T" (**A**minoglycosides, **T**etracyclines). * **Aminoglycosides** are the only protein synthesis inhibitors that are **bactericidal** (most others are bacteriostatic) [3]. * **Linezolid** is a drug of choice for MRSA and VRE but can cause **thrombocytopenia** and **Serotonin Syndrome** when co-administered with SSRIs.
Explanation: **Explanation:** **Ivermectin** is a broad-spectrum anthelmintic agent derived from *Streptomyces avermitilis*. It is the drug of choice for several helminthic infections, most notably acting as a potent **microfilaricide**. **Why C is Correct:** Ivermectin works by intensifying GABA-mediated neurotransmission or binding to glutamate-gated chloride channels in invertebrate nerve and muscle cells. This leads to hyperpolarization, paralysis, and death of the parasite. It is highly effective against the microfilariae of *Onchocerca volvulus* (River blindness) and *Wuchereria bancrofti* (Lymphatic filariasis). While it kills microfilariae, it has little effect on adult worms (macrofilariae). **Analysis of Incorrect Options:** * **A & B (Cysticide/Taenicide):** These terms refer to drugs active against tapeworms (Cestodes) and their larval forms (e.g., Neurocysticercosis). **Praziquantel** and **Albendazole** are the preferred agents for these conditions. Ivermectin has no significant activity against Cestodes or Trematodes. * **D (Anti-amoebic):** Infections caused by *Entamoeba histolytica* are treated with luminal amebicides (e.g., Paromomycin) or tissue amebicides (e.g., Metronidazole). Ivermectin does not possess anti-protozoal activity. **High-Yield NEET-PG Pearls:** * **Drug of Choice (DOC):** Ivermectin is the DOC for **Strongyloidiasis**, **Onchocerciasis**, and **Scabies** (oral). * **Mazzotti Reaction:** When treating Onchocerciasis, the rapid death of microfilariae can trigger an immune response (fever, rash, hypotension). Ivermectin is preferred over Diethylcarbamazine (DEC) because it causes a less severe reaction. * **Safety:** It does not cross the blood-brain barrier in humans (due to P-glycoprotein efflux), making it safe at therapeutic doses.
Explanation: **Explanation:** **Pseudomembranous enterocolitis** is caused by the overgrowth of *Clostridioides difficile* (C. diff) following the suppression of normal intestinal flora by broad-spectrum antibiotics. **Why Vancomycin is the correct answer:** Vancomycin (specifically the oral formulation) is actually a **treatment** for pseudomembranous enterocolitis. It is a glycopeptide antibiotic that is not absorbed from the GI tract, allowing it to reach high concentrations in the colon where it kills *C. difficile*. Because it targets the causative organism rather than predisposing the patient to its overgrowth, it does not cause the condition. **Analysis of incorrect options:** Almost any antibiotic can theoretically cause C. diff infection, but certain classes are notorious "high-risk" triggers: * **Clindamycin (Option C):** Historically the most classically associated antibiotic with pseudomembranous colitis. * **Ceftazidime (Option D):** 3rd and 4th generation Cephalosporins are currently the most common triggers in hospital settings due to their broad-spectrum activity. * **Levofloxacin (Option B):** Fluoroquinolones are frequently implicated in outbreaks and are major risk factors for C. diff. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** Oral Vancomycin or Fidaxomicin are the first-line treatments for C. diff. * **Metronidazole:** Previously the first-line agent, it is now reserved for mild cases if Vancomycin is unavailable. * **Mechanism:** *C. difficile* produces Toxin A (enterotoxin) and Toxin B (cytotoxin); Toxin B is primarily responsible for the mucosal damage and "pseudomembrane" formation. * **Diagnosis:** Confirmed by detecting C. diff toxins in stool or via sigmoidoscopy showing yellow-white plaques.
Explanation: **Explanation:** The correct answer is **Rifampicin**. **Why Rifampicin is the correct answer:** Rifampicin is a potent **inducer of the Cytochrome P450 (CYP450) enzyme system**, specifically the CYP3A4 isoenzyme. Most Protease Inhibitors (PIs) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) used in HAART are substrates of this same enzyme system. By inducing these enzymes, Rifampicin significantly increases the metabolism of antiretroviral drugs, leading to sub-therapeutic plasma levels, treatment failure, and the potential development of drug-resistant HIV strains. **Why the other options are incorrect:** * **Isoniazid (INH):** While INH can inhibit certain CYP enzymes, it does not have the profound inducing effect on HAART metabolism that Rifampicin does. Its primary interaction concern is peripheral neuropathy, which can be additive if the patient is on Stavudine (d4T). * **Ethambutol:** This drug is primarily excreted renally and does not significantly interfere with the hepatic microsomal enzyme system. * **Pyrazinamide:** Like Ethambutol, Pyrazinamide does not have significant induction or inhibition effects on the CYP450 system and does not interfere with the efficacy of HAART. **High-Yield Clinical Pearls for NEET-PG:** * **The "Rifabutin" Alternative:** In HIV patients on HAART, **Rifabutin** is often substituted for Rifampicin because it is a much less potent inducer of CYP3A4, making it safer to co-administer with Protease Inhibitors. * **Drug of Choice:** For TB in HIV patients, the standard "RHZE" regimen is used, but the HAART regimen may need adjustment (e.g., using Efavirenz-based regimens or Integrase Inhibitors like Dolutegravir at a higher dose). * **IRIS:** Be aware of **Immune Reconstitution Inflammatory Syndrome (IRIS)**, which can occur when starting HAART in a TB patient due to a sudden recovery of the immune response against TB antigens.
Explanation: **Explanation:** Linezolid is an oxazolidinone antibiotic used primarily for resistant Gram-positive infections like MRSA and VRE. The question asks for the exception among its known toxicities. While gastrointestinal upset can occur with many antibiotics, **Vomiting** is not considered a characteristic or "signature" toxicity of linezolid in the context of medical examinations, whereas the other options are classic, high-yield side effects associated with its unique mechanism of action. **Analysis of Options:** * **Thrombocytopenia (Option A):** This is the most common hematologic abnormality. Linezolid causes reversible bone marrow suppression (myelosuppression), particularly when used for more than 2 weeks. Monitoring CBC is mandatory. * **Lactic Acidosis (Option B):** Linezolid can inhibit mitochondrial protein synthesis. This mitochondrial toxicity leads to a shift toward anaerobic metabolism, resulting in lactic acidosis. * **Peripheral Neuropathy (Option D):** Long-term use (usually >28 days) is strongly associated with both peripheral and optic neuropathy. Optic neuropathy can lead to vision loss and requires immediate discontinuation. **Clinical Pearls for NEET-PG:** 1. **MAO Inhibition:** Linezolid is a non-selective inhibitor of Monoamine Oxidase (MAO). It can precipitate **Serotonin Syndrome** if co-administered with SSRIs or tyramine-rich foods. 2. **Mechanism:** It inhibits protein synthesis by binding to the **23S ribosomal RNA of the 50S subunit**, preventing the formation of the 70S initiation complex. 3. **Resistance:** Resistance occurs via mutations in the 23S rRNA. 4. **Bioavailability:** It has nearly **100% oral bioavailability**, allowing an easy switch from IV to oral dosing.
Explanation: The treatment of chloroquine-resistant *Plasmodium falciparum* (CRPF) requires drugs that remain effective despite the parasite's efflux mechanisms. **Mefloquine** is a high-yield choice for this purpose [1, 2].
Explanation: ### Explanation **Correct Answer: B. Neomycin** **Mechanism of Neuromuscular Blockade (NMB):** Aminoglycosides can induce neuromuscular blockade by inhibiting the pre-junctional release of **Acetylcholine (ACh)** and reducing the sensitivity of the post-junctional nicotinic receptors. This effect is primarily due to the competitive inhibition of **Calcium ions** at the presynaptic nerve terminal. Among all aminoglycosides, **Neomycin** is the most potent inhibitor of ACh release, followed closely by Kanamycin [1]. Because of this high toxicity profile, Neomycin is never administered parenterally; it is restricted to topical use or oral administration for bowel preparation/hepatic coma. **Analysis of Incorrect Options:** * **D. Kanamycin:** While Kanamycin carries a significant risk of NMB (second only to Neomycin), it is clinically less potent in this regard than Neomycin [1]. The use of kanamycin has declined because it is among the most toxic aminoglycosides [1]. * **A. Tobramycin & C. Amikacin:** These are commonly used parenteral aminoglycosides. While they still carry a theoretical risk of NMB, their potential to cause respiratory paralysis is significantly lower than that of Neomycin or Kanamycin. **NEET-PG High-Yield Clinical Pearls:** 1. **Order of Potency for NMB:** Neomycin > Kanamycin > Amikacin > Gentamicin > Tobramycin. 2. **Reversal:** Aminoglycoside-induced NMB is best reversed by **Intravenous Calcium Gluconate** (antagonizes the calcium-blocking effect). Neostigmine may also be used but is less reliably effective [2]. 3. **Contraindication:** Aminoglycosides are strictly contraindicated in patients with **Myasthenia Gravis**, as they can precipitate a severe myasthenic crisis. 4. **Drug Interaction:** Risk increases significantly when used concurrently with skeletal muscle relaxants (e.g., Succinylcholine or Vecuronium) [3].
Explanation: **Explanation:** Sulfonamides are classified based on their pharmacokinetic profile, specifically their duration of action, which is determined by their rate of renal excretion and protein binding. **Why Sulphadoxine is correct:** **Sulphadoxine** is categorized as an **ultra-long-acting sulfonamide**. It has an exceptionally long half-life of approximately **7 to 9 days (170–200 hours)**. This is due to its high degree of plasma protein binding and slow renal clearance. Because of this prolonged action, it is not used for routine infections but is primarily used in combination with Pyrimethamine (Fansidar) for the prophylaxis and treatment of chloroquine-resistant *Plasmodium falciparum* malaria. **Analysis of Incorrect Options:** * **Sulphadiazine:** This is a **short-acting** sulfonamide with a half-life of about 10 hours. It is commonly used in the treatment of UTI and, in combination with pyrimethamine, is the first-line treatment for Toxoplasmosis. * **Sulphacetamide:** This is a highly soluble sulfonamide used primarily **topically** in the eye for bacterial conjunctivitis. It is not used for its systemic long-acting properties. * **Mafenide:** This is a **topical** sulfonamide used primarily in burn dressings to prevent infection (especially *Pseudomonas*). It is not administered orally for systemic effect and is known for causing metabolic acidosis as a side effect. **High-Yield NEET-PG Pearls:** * **Mechanism of Action:** Sulfonamides are structural analogs of PABA; they competitively inhibit **Dihydropteroate Synthase**. * **Shortest acting sulfonamide:** Sulfisoxazole. * **Drug of choice for Nocardiosis:** Sulfonamides (usually Cotrimoxazole). * **Key Side Effect:** Stevens-Johnson Syndrome (SJS) and Crystalluria (prevented by alkalinizing urine and increasing fluid intake).
Explanation: **Mechanism of Action: Ivermectin** **Correct Answer: C. Activation of Glutamate-gated Chloride channels** Ivermectin is a broad-spectrum anthelmintic agent that works by binding selectively and with high affinity to **glutamate-gated chloride ion channels** located in invertebrate nerve and muscle cells. This binding increases the permeability of the cell membrane to chloride ions, leading to **hyperpolarization** of the nerve or muscle cell. The result is tonic paralysis and eventual death of the parasite. In humans, ivermectin does not easily cross the blood-brain barrier, which protects our GABA receptors from similar effects. **Analysis of Incorrect Options:** * **A. Inhibition of pyruvate ferredoxin oxidoreductase:** This is the mechanism of action for **Nitazoxanide** and **Metronidazole** (in anaerobic bacteria/protozoa like *Giardia* and *Entamoeba*). It interferes with anaerobic energy metabolism. * **B. Inhibition of Nicotinic Acetylcholine receptor:** This describes the action of neuromuscular blockers or certain insecticides. In contrast, **Pyrantel pamoate** acts as a nicotinic receptor *agonist* (depolarizing neuromuscular blocker) in helminths. * **D. Inhibition of heme polymerase:** This is the mechanism of **Chloroquine** and other aminoquinolines. It prevents the detoxification of heme into hemozoin in malaria parasites, leading to toxic heme accumulation. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Strongyloidiasis, Onchocerciasis (River blindness), Scabies (oral), and *Larva currens*. * **Mazzotti Reaction:** A severe immune response (fever, rash, hypotension) seen after treating Onchocerciasis with ivermectin due to the rapid death of microfilariae. * **Safety:** Contraindicated in conditions where the blood-brain barrier is compromised (e.g., meningitis, African Sleeping Sickness).
Explanation: **Explanation:** *Mycobacterium avium* complex (MAC) is a group of non-tuberculous mycobacteria (NTM) that frequently causes opportunistic infections in immunocompromised patients, particularly those with HIV/AIDS (CD4 count <50 cells/mm³). **Why Clarithromycin is correct:** Clarithromycin (or Azithromycin) is the **drug of choice** for both the prophylaxis and treatment of MAC infections. Macrolides inhibit protein synthesis by binding to the 50S ribosomal subunit. For active MAC infection, Clarithromycin is typically used in combination with Ethambutol and sometimes Rifabutin to prevent the emergence of resistance. **Why the other options are incorrect:** * **Isoniazid (A):** While it is a primary (first-line) drug for *M. tuberculosis*, MAC is intrinsically resistant to Isoniazid due to differences in the cell wall and metabolic pathways. * **Cycloserine (C):** This is a second-line drug used for Multidrug-Resistant Tuberculosis (MDR-TB). It has minimal clinical utility against MAC. * **Rifampicin (D):** Although Rifampicin is a first-line anti-TB drug, it is generally less effective against MAC than its derivative, **Rifabutin**, which is preferred in MAC regimens due to higher potency and fewer drug interactions in HIV patients. **High-Yield Clinical Pearls for NEET-PG:** * **Prophylaxis:** Start Azithromycin or Clarithromycin in HIV patients when CD4 count falls below **50 cells/mm³**. * **Treatment Regimen:** The standard "triple therapy" for MAC includes **Clarithromycin + Ethambutol + Rifabutin**. * **Side Effect:** Monitor for metallic taste and GI upset with Clarithromycin; monitor for uveitis and orange discoloration of secretions with Rifabutin.
Beta-Lactam Antibiotics
Practice Questions
Aminoglycosides
Practice Questions
Macrolides and Ketolides
Practice Questions
Tetracyclines
Practice Questions
Quinolones
Practice Questions
Sulfonamides and Trimethoprim
Practice Questions
Antimycobacterial Drugs
Practice Questions
Antifungal Agents
Practice Questions
Antiviral Drugs
Practice Questions
Antiparasitic Agents
Practice Questions
Principles of Antimicrobial Selection
Practice Questions
Antimicrobial Resistance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free